September 12, 2022 — The Baszucki, Dauten, and Brin families joined with the Milken Institute to launch BD²: Breakthrough Discoveries for thriving with Bipolar Disorder. As the largest private investment focused on the study of bipolar disorder, BD² provides an unprecedented opportunity to identify breakthroughs in scientific understanding that create new interventions so that everyone with bipolar disorder can thrive.

September 6, 2022 — The FDA has approved the SAINT Neuromodulation System for the treatment of major depressive disorder in adults who have not seen improvement using antidepressant medications. The Baszuckis are proud to have partnered with Nolan Williams and Magnus Medical to make this timely and personalized treatment accessible to patients with debilitating conditions.